Penumbra reported second-quarter 2026 financial results with GAAP earnings per share of $0.88 and total revenue of $390 million. Global thrombectomy revenue reached $259.0 million, a 12.5% increase from the second quarter of 2025, while global embolization and access revenue rose 20.0% to $131.1 million. Gross profit margin improved to 67.9%, up 1.9 percentage points year-over-year. Total operating expenses were $223.9 million, including $25.4 million in research and development and $198.5 million in selling, general and administrative costs, which contained $6.9 million in acquisition-related expenses tied to the pending acquisition of Penumbra by Boston Scientific Corporation. Income from operations was $41.0 million and net income was $34.8 million.
Penumbra IncPenumbra reported Q2 GAAP EPS of $0.88 on revenue of $390M, with revenue growth in both thrombectomy and embolization segments and improved gross margin.
Boston Scientific CorpPenumbra's strong Q2 results and improved margins support the pending acquisition by Boston Scientific, making the deal more attractive.